The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...

Shares in Spanish pharma group Grifols have plummeted after UK-based hedge fund Gotham City Research issued a report claiming it has fraudulently manipulated its financial reporting by not ...

In response, Grifols, a global leader in plasma science and the production of plasma-derived medicines, has embarked on a groundbreaking program in partnership with The Michael J. Fox Foundation ...

Muddy Waters CEO Carson Block picked Grifols (GRFS) as a short for the Robin Hood Foundation’s stock picking contest. However, said in an interview that Muddy Waters is “not actually short it ...

In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the other pharma stocks. The Rising Demand for Weight-Loss Medications and GLP-1 Developments ...

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes ...

Grifols (GRFS) hosted it 2025 Capital Markets Day on February 27 in London, where the company announced it would double revenue to EUR 14 billion over the next decade as part of an ambitious ...

Grifols expects to boost revenue and free cash flow, shares soar Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the ...